A benefit with nivolumab plus chemotherapy was seen across PD-L1 subgroups in CheckMate 816 study, with a greater event-free survival benefit in patients with a tumor PD-L1 expression level of 1% or more than in those with a level of less than 1% (18, 37). The gene discussed is CD274; the disease is neoplasm.